{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:15:06Z","timestamp":1788275706031,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100016387","name":"Grifols","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03769-z","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:45:15Z","timestamp":1788273915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early Use of Fostamatinib in Immune Thrombocytopenia"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9575-1816","authenticated-orcid":false,"given":"Tom\u00e1s Jos\u00e9","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Bermejo-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Cardesa-Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Acedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefa","family":"Luis-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Lakhwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bernat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo Enrique","family":"Haces-Tirado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mart\u00ednez-Carballeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Hern\u00e1ndez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyes","family":"Jimenez-B\u00e1rcenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Navas-Elorza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shally","family":"Marcellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Torres-Tienza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Perona-Bl\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Benet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Fernandez-Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"L\u00f3pez-Santamar\u00eda Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro","family":"Jarque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Gonz\u00e1lez-Gasc\u00f3n-y-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Garc\u00eda-Don\u00e1s Gabald\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"3769_CR1","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1056\/NEJMra010501","volume":"346","author":"DB Cines","year":"2002","unstructured":"Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995\u20131008.","journal-title":"N Engl J Med"},{"key":"3769_CR2","doi-asserted-by":"publisher","first-page":"103820","DOI":"10.1016\/j.ebiom.2022.103820","volume":"76","author":"D Provan","year":"2022","unstructured":"Provan D, Semple JW. Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine. 2022;76:103820.","journal-title":"EBioMedicine"},{"key":"3769_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1365-2141.2010.08412.x","volume":"152","author":"LJ Toltl","year":"2011","unstructured":"Toltl LJ, Arnold DM. Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters. Br J Haematol. 2011;152:52\u201360.","journal-title":"Br J Haematol"},{"key":"3769_CR4","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386\u201393.","journal-title":"Blood"},{"key":"3769_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1600-0609.2008.01206.x","volume":"82","author":"M Michel","year":"2009","unstructured":"Michel M. Immune thrombocytopenic purpura: epidemiology and implications for patients. Eur J Haematol Suppl. 2009;82:3\u20137.","journal-title":"Eur J Haematol Suppl"},{"key":"3769_CR6","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1046\/j.1365-2141.2003.04547.x","volume":"122","author":"AJ Neylon","year":"2003","unstructured":"Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122:966\u201374.","journal-title":"Br J Haematol"},{"key":"3769_CR7","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/hematology.2024000594","volume":"2024","author":"W Ghanima","year":"2024","unstructured":"Ghanima W, Cuker A, Michel M. Insights on treatment of adult ITP: algorithm for management and role of multimodal therapy. Hematol Am Soc Hematol Educ Program. 2024;2024:678\u201384.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"3769_CR8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2015-07-659656","volume":"127","author":"Y Wei","year":"2016","unstructured":"Wei Y, Ji XB, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016;127:296\u2013302.","journal-title":"Blood"},{"key":"3769_CR9","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1056\/NEJMoa030254","volume":"349","author":"Y Cheng","year":"2003","unstructured":"Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349:831\u20136.","journal-title":"N Engl J Med"},{"key":"3769_CR10","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1182\/blood-2005-12-015222","volume":"109","author":"MG Mazzucconi","year":"2007","unstructured":"Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007;109:1401\u20137.","journal-title":"Blood"},{"key":"3769_CR11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2147\/JBM.S259101","volume":"12","author":"F Song","year":"2021","unstructured":"Song F, Al-Samkari H. Management of adult patients with immune thrombocytopenia (ITP): a review on current guidance and experience from clinical practice. J Blood Med. 2021;12:653\u201364.","journal-title":"J Blood Med"},{"key":"3769_CR12","doi-asserted-by":"publisher","first-page":"204062071984173","DOI":"10.1177\/2040620719841735","volume":"10","author":"H Al-Samkari","year":"2019","unstructured":"Al-Samkari H, Kuter DJ. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719841735.","journal-title":"Ther Adv Hematol"},{"key":"3769_CR13","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","volume":"104","author":"W Ghanima","year":"2019","unstructured":"Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104:1112\u201323.","journal-title":"Haematologica"},{"key":"3769_CR14","doi-asserted-by":"publisher","first-page":"204062072110108","DOI":"10.1177\/20406207211010875","volume":"12","author":"N Cooper","year":"2021","unstructured":"Cooper N, Altomare I, Thomas MR, et al. Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib. Ther Adv Hematol. 2021;12:20406207211010876.","journal-title":"Ther Adv Hematol"},{"key":"3769_CR15","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","volume":"3","author":"D Provan","year":"2019","unstructured":"Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3:3780\u2013817.","journal-title":"Blood Adv"},{"key":"3769_CR16","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829\u201366.","journal-title":"Blood Adv"},{"key":"3769_CR17","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1182\/blood-2003-08-2672","volume":"103","author":"R McMillan","year":"2004","unstructured":"McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103:1364\u20139.","journal-title":"Blood"},{"key":"3769_CR18","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1182\/blood-2003-01-0275","volume":"103","author":"EJ Houwerzijl","year":"2004","unstructured":"Houwerzijl EJ, Blom NR, van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004;103:500\u20136.","journal-title":"Blood"},{"key":"3769_CR19","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/nm921","volume":"9","author":"B Olsson","year":"2003","unstructured":"Olsson B, Andersson PO, Jern\u00e5s M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9:1123\u20134.","journal-title":"Nat Med"},{"key":"3769_CR20","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1124\/jpet.106.109058","volume":"319","author":"S Braselmann","year":"2006","unstructured":"Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signalling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006;319:998\u20131008.","journal-title":"J Pharmacol Exp Ther"},{"key":"3769_CR21","doi-asserted-by":"publisher","first-page":"6294","DOI":"10.3390\/jcm13216294","volume":"13","author":"ME Mingot-Castellano","year":"2024","unstructured":"Mingot-Castellano ME, Garc\u00eda-Donas G, Campos-\u00c1lvarez RM, det al. Platelet responses after tapering and discontinuation of fostamatinib in patients with immune thrombocytopenia: a continuation of the Fostasur study. J Clin Med. 2024;13:6294.","journal-title":"J Clin Med"},{"key":"3769_CR22","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.25125","volume":"93","author":"J Bussel","year":"2018","unstructured":"Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase\u00a03 randomized placebo-controlled trials. Am J Hematol. 2018;93:921\u201330.","journal-title":"Am J Hematol"},{"key":"3769_CR23","unstructured":"Tavlesse (fostamatinib) summary of product characteristics. European Medicines Agency; 2024."},{"key":"3769_CR24","first-page":"9953245","volume":"2023","author":"V Innao","year":"2023","unstructured":"Innao V, Calogero RD, Lo Presti F, Consoli U. Two refractory immune thrombocytopenia case reports showing responsiveness to fostamatinib. Case Rep Hematol. 2023;2023:9953245.","journal-title":"Case Rep Hematol"},{"key":"3769_CR25","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/bjh.18582","volume":"200","author":"M Kuwana","year":"2023","unstructured":"Kuwana M, Ito T, Kowata S, et al. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: a phase\u00a03 placebo-controlled double-blind study. Br J Haematol. 2023;200:802\u201311.","journal-title":"Br J Haematol"},{"key":"3769_CR26","doi-asserted-by":"publisher","first-page":"8119270","DOI":"10.1155\/2022\/8119270","volume":"2022","author":"J Liu","year":"2022","unstructured":"Liu J, Hsia CC. The efficacy and safety of fostamatinib in elderly patients with immune thrombocytopenia: a single-centre real-world case series. Adv Hematol. 2022;2022:8119270.","journal-title":"Adv Hematol"},{"key":"3769_CR27","doi-asserted-by":"publisher","first-page":"109109","DOI":"10.1016\/j.thromres.2024.109109","volume":"241","author":"A Saldanha","year":"2024","unstructured":"Saldanha A, Colella MP, Villa\u00e7a PR, Thachil J, Orsi FA. The immune thrombocytopenia paradox: should we be concerned about thrombosis in ITP? Thromb Res. 2024;241:109109.","journal-title":"Thromb Res"},{"key":"3769_CR28","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/jth.12636","volume":"12","author":"M Ruggeri","year":"2014","unstructured":"Ruggeri M, Tosetto A, Palandri F, et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost. 2014;12:1266\u201373.","journal-title":"J Thromb Haemost"},{"key":"3769_CR29","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1182\/blood.2024024250","volume":"144","author":"TJ Gonz\u00e1lez-L\u00f3pez","year":"2024","unstructured":"Gonz\u00e1lez-L\u00f3pez TJ, Bermejo-Vega N, Cardesa-Cabrera R, et al. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice. Blood. 2024;144:646\u201356.","journal-title":"Blood"},{"issue":"Suppl 16","key":"3769_CR30","doi-asserted-by":"publisher","first-page":"e23289","DOI":"10.1200\/JCO.2024.42.16_suppl.e23289","volume":"42","author":"R Goel","year":"2024","unstructured":"Goel R, Azhar W, Numerof RP, Chow D, Shah B. Real-world experience with fostamatinib in patients with immune thrombocytopenia: results of an observational study (FORTE). J Clin Oncol. 2024;42(Suppl 16):e23289.","journal-title":"J Clin Oncol"},{"key":"3769_CR31","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/bjh.16959","volume":"190","author":"R Boccia","year":"2020","unstructured":"Boccia R, Cooper N, Ghanima W, et al. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. Br J Haematol. 2020;190:933\u20138.","journal-title":"Br J Haematol"},{"key":"3769_CR32","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/bjh.19602","volume":"205","author":"ME Mingot-Castellano","year":"2024","unstructured":"Mingot-Castellano ME, Bastida JM, Ghanima W, et al. Avatrombopag plus fostamatinib combination as treatment in patients with multirefractory immune thrombocytopenia. Br J Haematol. 2024;205:1551\u20135.","journal-title":"Br J Haematol"},{"key":"3769_CR33","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1111\/bjh.19443","volume":"204","author":"R Jim\u00e9nez-B\u00e1rcenas","year":"2024","unstructured":"Jim\u00e9nez-B\u00e1rcenas R, Garc\u00eda-Donas-Gabald\u00f3n G, Campos-\u00c1lvarez RM, et al. Treatment with fostamatinib in patients with immune thrombocytopenia: experience from the Andalusian region in Spain (FOSTASUR study). Br J Haematol. 2024;204:1977\u201385.","journal-title":"Br J Haematol"},{"key":"3769_CR34","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1111\/bjh.70069","volume":"207","author":"E Lucchini","year":"2025","unstructured":"Lucchini E, Vianelli N, Consoli U, et al. Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience (GIMEMA ITP1122 study). Br J Haematol. 2025;207:2529\u201338.","journal-title":"Br J Haematol"},{"key":"3769_CR35","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/ajh.70194","volume":"101","author":"G Moulis","year":"2026","unstructured":"Moulis G, Mah\u00e9vas M, Viallard JF, et al. Real-world effectiveness and safety of fostamatinib in difficult-to-treat immune thrombocytopenia patients: a prospective multicentre registry in France. Am J Hematol. 2026;101:736\u201345.","journal-title":"Am J Hematol"},{"key":"3769_CR36","doi-asserted-by":"publisher","first-page":"2456687","DOI":"10.1080\/16078454.2025.2456687","volume":"30","author":"W Ghanima","year":"2025","unstructured":"Ghanima W, Lucas Boronat FJ, Carrai V, Rackwitz S. Sustained response off treatment after fostamatinib in refractory immune thrombocytopenia: a series of four case reports. Hematology. 2025;30:2456687.","journal-title":"Hematology"},{"key":"3769_CR37","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3324\/haematol.2009.018390","volume":"95","author":"A Sarpatwari","year":"2010","unstructured":"Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia. Haematologica. 2010;95:1167\u201375.","journal-title":"Haematologica"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03769-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03769-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03769-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:45:17Z","timestamp":1788273917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03769-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":37,"alternative-id":["3769"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03769-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tom\u00e1s Jos\u00e9 Gonz\u00e1lez-L\u00f3pez has received research grants from Amgen and Novartis and speaker honoraria from Amgen, Novartis, Sobi, Grifols, and Argenx. Mar\u00eda Luisa Lozano reports grants and personal fees from Amgen and Terumo S.A., and personal fees from Alexion, Amgen, Argenx BV, Celgene, GlaxoSmithKline, Grifols, Novartis, Sobi, and UCB Biopharma. Daniel Mart\u00ednez-Carballeira has participated in advisory activities for Sobi. Reyes Jim\u00e9nez-B\u00e1rcenas has received speaker or advisor honoraria from Amgen, CSL Behring, Grifols, Novo Nordisk, Pfizer, Roche, and Sobi. Nuria Bermejo-Vega, Roc\u00edo Cardesa-Cabrera, Natalia Acedo, Josefa Luis-Navarro, Sunil Lakhwani, Silvia Bernat, Guillermo Enrique Haces-Tirado, Pilar Gal\u00e1n, Roberto Hern\u00e1ndez-Mart\u00edn, Bego\u00f1a Navas-Elorza, Shally Marcellini, Ana Torres-Tienza, \u00c1lvaro Perona-Bl\u00e1zquez, Carmen Benet, Dolores Fern\u00e1ndez-Jim\u00e9nez, Carolina L\u00f3pez-Santamar\u00eda Castro, Isidro Jarque, Violeta Mart\u00ednez, Isabel Gonz\u00e1lez-Gasc\u00f3n-y-Mar\u00edn, and Gloria Garc\u00eda-Don\u00e1s Gabald\u00f3n have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study procedures adhered to the ethical principles outlined in the Declaration of Helsinki. Approval was granted by the Ethics Committee of Hospital Universitario de Burgos (protocol code\u2014FOSTAMES), and oversight was provided by the institutional review boards of the participating centers. In addition, the study received authorization as a post-authorization observational investigation from the Spanish Agency of Medicines and Medical Devices. Written informed consent was obtained from each patient before any study-related data were collected.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}